Comparison of Treatment Effects Between Animal Experiments and Clinical Trials

Research output: Contribution to journalArticle

Standard

Comparison of Treatment Effects Between Animal Experiments and Clinical Trials. / Perel, P; Roberts, I; Sena, E; Wheble, P; Briscoe, C; Sandercock, P; Macleod, M; Mignini, LE; Jayaram, P; Khan, Khalid.

In: British Medical Journal, Vol. 334, No. 197, 27.01.2007.

Research output: Contribution to journalArticle

Harvard

Perel, P, Roberts, I, Sena, E, Wheble, P, Briscoe, C, Sandercock, P, Macleod, M, Mignini, LE, Jayaram, P & Khan, K 2007, 'Comparison of Treatment Effects Between Animal Experiments and Clinical Trials', British Medical Journal, vol. 334, no. 197. https://doi.org/10.1136/bmj.39048.407928.BE

APA

Perel, P., Roberts, I., Sena, E., Wheble, P., Briscoe, C., Sandercock, P., Macleod, M., Mignini, LE., Jayaram, P., & Khan, K. (2007). Comparison of Treatment Effects Between Animal Experiments and Clinical Trials. British Medical Journal, 334(197). https://doi.org/10.1136/bmj.39048.407928.BE

Vancouver

Author

Perel, P ; Roberts, I ; Sena, E ; Wheble, P ; Briscoe, C ; Sandercock, P ; Macleod, M ; Mignini, LE ; Jayaram, P ; Khan, Khalid. / Comparison of Treatment Effects Between Animal Experiments and Clinical Trials. In: British Medical Journal. 2007 ; Vol. 334, No. 197.

Bibtex

@article{697a036065b74368a1aa03a8feecbcad,
title = "Comparison of Treatment Effects Between Animal Experiments and Clinical Trials",
abstract = "Objective To examine concordance between treatment effects in animal experiments and clinical trials. Study design Systematic review. Data sources Medline, Embase, SIGLE, NTIS, Science Citation Index, CAB, BIOSIS. Study selection Animal studies for interventions with unambiguous evidence of a treatment effect (benefit or harm) in clinical. trials: head injury, antifibrinolytics in haemorrhage, thrombolysis in acute ischaemic stroke, tirilazad in acute ischaemic stroke, antenatal corticosteroids to prevent neonatal respiratory distress syndrome, and bisphosphonates in the prevention and treatment of osteoporosis. Review methods Data were extracted on study design, allocation concealment, number of randomised animals, type of model, intervention, and outcome. Results Corticosteroids did not show any benefit in clinical trials of treatment for head injury but did show a benefit in animal models (pooled odds ratio for adverse functional outcome 0.58, 95% confidence interval 0.41 to 0.83). Antifibrinolytics reduced bleeding in clinical trials but the data were inconclusive in animal models. Thrombolysis improved outcome in patients with ischaemic stroke. In animal models, tissue plasminogen activator reduced infarct volume by 24% (95% confidence interval 20% to 28%) and improved neurobehavioural scores by 23% (17% to 29%). Tirilazad was associated with a worse outcome in patients with ischaemic stroke. In animal models, tirilazad reduced infarct volume by 29% (21% to 37%) and improved neurobehavioural scores by 48% (29% to 67%). Antenatal corticosteroids reduced respiratory distress and mortality in neonates whereas in animal models respiratory distress was reduced but the effect on mortality was inconclusive (odds ratio 4.2, 95% confidence interval 0.85 to 20.9). Bisphosphonates increased bone mineral density in patients with osteoporosis. In animal models the bisphosphonate alendronate increased bone mineral density compared with placebo by 11.0% (95% confidence interval 9.2% to 12.9%) in the combined results for the hip region. The corresponding treatment effect in the lumbar spine was 8.5% (5.8% to 11.2%) and in the combined results for the forearms (baboons only) was 1.7% (-1.4% to 4.7%). Conclusions Discordance between animal and human studies may be due to bias or to the failure of animal models to mimic clinical disease adequately.",
author = "P Perel and I Roberts and E Sena and P Wheble and C Briscoe and P Sandercock and M Macleod and LE Mignini and P Jayaram and Khalid Khan",
year = "2007",
month = jan,
day = "27",
doi = "10.1136/bmj.39048.407928.BE",
language = "English",
volume = "334",
journal = "British Medical Journal",
issn = "0959-8138",
publisher = "BMJ Publishing Group",
number = "197",

}

RIS

TY - JOUR

T1 - Comparison of Treatment Effects Between Animal Experiments and Clinical Trials

AU - Perel, P

AU - Roberts, I

AU - Sena, E

AU - Wheble, P

AU - Briscoe, C

AU - Sandercock, P

AU - Macleod, M

AU - Mignini, LE

AU - Jayaram, P

AU - Khan, Khalid

PY - 2007/1/27

Y1 - 2007/1/27

N2 - Objective To examine concordance between treatment effects in animal experiments and clinical trials. Study design Systematic review. Data sources Medline, Embase, SIGLE, NTIS, Science Citation Index, CAB, BIOSIS. Study selection Animal studies for interventions with unambiguous evidence of a treatment effect (benefit or harm) in clinical. trials: head injury, antifibrinolytics in haemorrhage, thrombolysis in acute ischaemic stroke, tirilazad in acute ischaemic stroke, antenatal corticosteroids to prevent neonatal respiratory distress syndrome, and bisphosphonates in the prevention and treatment of osteoporosis. Review methods Data were extracted on study design, allocation concealment, number of randomised animals, type of model, intervention, and outcome. Results Corticosteroids did not show any benefit in clinical trials of treatment for head injury but did show a benefit in animal models (pooled odds ratio for adverse functional outcome 0.58, 95% confidence interval 0.41 to 0.83). Antifibrinolytics reduced bleeding in clinical trials but the data were inconclusive in animal models. Thrombolysis improved outcome in patients with ischaemic stroke. In animal models, tissue plasminogen activator reduced infarct volume by 24% (95% confidence interval 20% to 28%) and improved neurobehavioural scores by 23% (17% to 29%). Tirilazad was associated with a worse outcome in patients with ischaemic stroke. In animal models, tirilazad reduced infarct volume by 29% (21% to 37%) and improved neurobehavioural scores by 48% (29% to 67%). Antenatal corticosteroids reduced respiratory distress and mortality in neonates whereas in animal models respiratory distress was reduced but the effect on mortality was inconclusive (odds ratio 4.2, 95% confidence interval 0.85 to 20.9). Bisphosphonates increased bone mineral density in patients with osteoporosis. In animal models the bisphosphonate alendronate increased bone mineral density compared with placebo by 11.0% (95% confidence interval 9.2% to 12.9%) in the combined results for the hip region. The corresponding treatment effect in the lumbar spine was 8.5% (5.8% to 11.2%) and in the combined results for the forearms (baboons only) was 1.7% (-1.4% to 4.7%). Conclusions Discordance between animal and human studies may be due to bias or to the failure of animal models to mimic clinical disease adequately.

AB - Objective To examine concordance between treatment effects in animal experiments and clinical trials. Study design Systematic review. Data sources Medline, Embase, SIGLE, NTIS, Science Citation Index, CAB, BIOSIS. Study selection Animal studies for interventions with unambiguous evidence of a treatment effect (benefit or harm) in clinical. trials: head injury, antifibrinolytics in haemorrhage, thrombolysis in acute ischaemic stroke, tirilazad in acute ischaemic stroke, antenatal corticosteroids to prevent neonatal respiratory distress syndrome, and bisphosphonates in the prevention and treatment of osteoporosis. Review methods Data were extracted on study design, allocation concealment, number of randomised animals, type of model, intervention, and outcome. Results Corticosteroids did not show any benefit in clinical trials of treatment for head injury but did show a benefit in animal models (pooled odds ratio for adverse functional outcome 0.58, 95% confidence interval 0.41 to 0.83). Antifibrinolytics reduced bleeding in clinical trials but the data were inconclusive in animal models. Thrombolysis improved outcome in patients with ischaemic stroke. In animal models, tissue plasminogen activator reduced infarct volume by 24% (95% confidence interval 20% to 28%) and improved neurobehavioural scores by 23% (17% to 29%). Tirilazad was associated with a worse outcome in patients with ischaemic stroke. In animal models, tirilazad reduced infarct volume by 29% (21% to 37%) and improved neurobehavioural scores by 48% (29% to 67%). Antenatal corticosteroids reduced respiratory distress and mortality in neonates whereas in animal models respiratory distress was reduced but the effect on mortality was inconclusive (odds ratio 4.2, 95% confidence interval 0.85 to 20.9). Bisphosphonates increased bone mineral density in patients with osteoporosis. In animal models the bisphosphonate alendronate increased bone mineral density compared with placebo by 11.0% (95% confidence interval 9.2% to 12.9%) in the combined results for the hip region. The corresponding treatment effect in the lumbar spine was 8.5% (5.8% to 11.2%) and in the combined results for the forearms (baboons only) was 1.7% (-1.4% to 4.7%). Conclusions Discordance between animal and human studies may be due to bias or to the failure of animal models to mimic clinical disease adequately.

UR - http://www.scopus.com/inward/record.url?scp=33846677129&partnerID=8YFLogxK

U2 - 10.1136/bmj.39048.407928.BE

DO - 10.1136/bmj.39048.407928.BE

M3 - Article

VL - 334

JO - British Medical Journal

JF - British Medical Journal

SN - 0959-8138

IS - 197

ER -